Laverock Therapeutics, a gene control company powering the development of disease-responsive advanced therapies, announces the expansion of its seed funding round, taking the total raised to more than £20m.
The investment was led by Calculus Capital, with participation from existing investors Eli Lilly and Company, Mercia Ventures, Eos Advisory and Maven Capital Partners.
The company also welcomed a new investor, Norcliffe Capital. This additional investment marks a transformational period for Laverock.
The company has achieved platform development and validation and is transitioning to lead product selection, reporting positive functional data for both its primary T-cell and Macrophage programmes, demonstrating enhanced tumour control in haematological and solid tumour cancer models.
Laverock’s unique platform technologies provide the potential to transform the efficacy, precision and safety of advanced therapies through the implementation of its programmable, tunable and multiplex gene silencing approach.
Elizabeth Klein, Investment Director at Calculus, said: “We are delighted to continue our support for Laverock’s progress in pioneering a new era of programmable advanced therapies."
"This new data and expanded funding demonstrate the potential of Laverock’s technologies."
"We look forward to continuing our work with David and the team as they drive forward product development opportunities, as well as delivering value for our investors.”
David Venables, CEO of Laverock, added: “The Laverock team has been busy in recent months, continuing to validate our technology platforms but also generating functional data for our therapeutic programmes."
"This new funding will enable us to continue this development, as well as form partnerships and collaborations to integrate our technologies into partners’ therapeutic pipelines. I’d like to thank all our existing and new investors for their continued support.”
To reflect Laverock’s recent progress, the company has updated its corporate identity, including the launch of a new website to demonstrate the expansion of its platform technologies and facilitate an enhanced focus on partnering and outlicensing activities.
